Novo Nordisk said on Tuesday that it will invest about 4 billion yuan ($555.7 million) to expand its existing production site in Tianjin, marking a major move in the country for the Denmark-based pharmaceutical company.
This follows a prior 1.18 billion yuan investment in finished production and pre-filled lines in the Tianjin Economic and Technological Development Area during the first quarter of 2023, signifying its continued commitment to growth and innovation in the region.
Lars Arnoldsen, corporate vice-president of Novo Nordisk, said, "With the expansion project, we'll be able to further increase manufacturing capability to support the localization of more innovative medicines, delivering the highest quality to patients."
The expansion project encompasses the development of a state-of-the-art filling facility equipped with isolator technology and is slated for completion in 2027.
